EPO Patent Bulletin - Pharma (A61K)

Cyanopyrrolidines USP30 Inhibitors Treat Fibrosis

Cyanopyrrolidines USP30 Inhibitors Treat Fibrosis

Sustained-Release Pharmaceutical Compositions Comprising an Immunomodulating Agent

The European Patent Office has published patent application EP3866764A1 for sustained-release pharmaceutical compositions comprising immunomodulating agents, filed by Taiwan Liposome Company, Ltd. and TLC Biopharmaceuticals, Inc. The patent covers liposomal drug delivery systems for immunomodulating agents with sustained-release properties. The patent affects pharmaceutical manufacturers and companies developing drug delivery systems. It grants exclusive rights to the applicants for the claimed compositions and uses in designated European states including Germany, France, the United Kingdom, Italy, Spain, and other EPC contracting states.

Anti-CD45 Antibodies and Conjugates - EP3877416A1, Regeneron Pharmaceuticals

The European Patent Office published patent application EP3877416A1 by Regeneron Pharmaceuticals, Inc. covering anti-CD45 antibodies and conjugates thereof. The patent is classified under IPC categories C07K 16/28, C07K 16/18, A61P 35/02, A61K 39/395, A61K 47/68, and A61K 39/00. The application is designated across 31 European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Anti-TREM2 Antibodies for Cancer Treatment

The European Patent Office published EP3893931A1, a patent application titled 'Methods of Using Anti-TREM2 Antibodies' filed by Pionyr Immunotherapeutics, Inc. The invention covers anti-TREM2 antibodies for cancer treatment (A61P 35/00). The patent designates all EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Indazole Derivatives DGAT2 Inhibitors

The European Patent Office published patent application EP3541374A1 for indazole derivatives useful as diacylglyceride O-acyltransferase 2 (DGAT2) inhibitors, filed by Merck Sharp & Dohme LLC. The application covers heterocyclic compounds classified under A61K 31/381, C07D 231/56 and related subclasses. The patent application is designated for all European Patent Convention contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Intellia Therapeutics Genome Editing Patent EP3687581A1

The European Patent Office published patent EP3687581A1 for Intellia Therapeutics, Inc., covering polynucleotides, compositions, and methods for genome editing. The patent application was published on April 1, 2026, with inventors including Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, and Seth C. Alexander. The patent designates 32 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Method for Treating Cancer Patients with Severe Renal Dysfunction - Taiho Pharmaceutical EP3412295A1

The European Patent Office granted patent EP3412295A1 to Taiho Pharmaceutical Co., Ltd. on April 1, 2026. The patent covers a method for treating cancer patients with severe renal dysfunction using pharmaceutical compositions containing specified active pharmaceutical ingredients. The patent applies to all designated European contracting states including DE, FR, GB, IT, ES, and NL.

SQZ Biotech Patent EP3765068A2, Apr 01, 2026, Immune Response

SQZ Biotech Patent EP3765068A2, Apr 01, 2026, Immune Response

TRAF 6 Inhibitors - Helmholtz Zentrum München - EP3768678A1

The European Patent Office granted Patent EP3768678A1 to Helmholtz Zentrum München for TRAF 6 inhibitors. The patent covers therapeutic compounds classified under A61K 31/5025 with applications including neurological disorders (A61P 25/16), cardiovascular diseases (A61P 9/00), cancer (A61P 35/00), diabetes (A61P 3/10), and immunological conditions (A61P 37/00). The patent is designated for all European contracting states including DE, FR, GB, IT, ES, and others.

Asenapine Transdermal Patch (LTS Lohmann)

The European Patent Office granted patent EP3810099A1 to LTS Lohmann Therapie-Systeme AG for a transdermal therapeutic system containing Asenapine. The patent covers a transdermal formulation (A61K 9/70) with Asenapine (A61K 31/407) and associated excipients. The patent is designated for all European contracting states including Germany, France, UK, Italy, Spain, Netherlands, Belgium, Austria, Switzerland, and 21 other states.